We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Collaboration to leverage Steritas’ STOX Suite in developing innovative treatments for autoimmune diseases.

BOSTON--Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Argenx Se (ARGX – Research Report). The company’s shares closed last Friday at $564.23. Don't Miss our Black Friday ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 1.0% in the third quarter, ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

SE (NASDAQ:ARGX – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $595.04, but opened at $572.41. argenx shares last traded at ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

周二,Wolfe Research将argenx SE (NASDAQ: ARGX)的股票评级从Peerperform上调至Outperform,目标价为697.00美元。该公司预计,在肌炎和PFS项目的推动下,argenx到2025年将呈现积极发展态势,并有望在重症肌无力(MG)市场保持主导地位,尤其是在竞争对手Biohaven和Immunovant发布最新消息后。 Wolfe Research ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer Perform, citing higher confidence in the company's dominance in the ...